BioLife Solutions (BLFS) Investor Presentation - Slideshow

Market Overview and Growth - Active clinical trials show cell therapies at 46%, gene therapies at 18%, and tissue-engineered therapies at 2%[1] - BioLife Solutions anticipates exiting 2024 with a $250 million revenue run rate and 30% adjusted EBITDA[20] - The company has seen rapid growth organically and via M&A, with 2022 unaudited preliminary revenue at $161.9 million[20] Products and Services - BioLife Solutions' biopreservation media is embedded in over 600 customer clinical applications[12] - The company launched 5 new products and 2 new services by the end of 2024[16] - Cell processing solutions are embedded in approximately 700 customer clinical applications[43] Financial Performance and Strategy - Approximately 60% of FY2022 revenue comes from recurring/high margin sources[14] - The company gained 102 new customers, including STEMCELL Technologies, in 2022[9] - BioLife Solutions anticipates approximately 70% recurring, high-margin revenue in 2025[371] Quality and Regulatory - The FDA is hiring 132 new staff in FY 2023 and an additional 96 in FY 2024-27 to meet demand in regulatory reviews and audits[2] - The company has ISO 9001, ISO 20387, FDA registered & inspected facilities since 2011[161]